• Genetic TherapyEnrolling

  Study to evaluate RCT2100 in adults with cystic fibrosis who are not eligible for/or not taking CFTR modulator therapy (Part 2) , protocol number ReCode RCT2100-101

  This study will evaluate the safety and tolerability of RTC2100, an investigational inhaled messenger RNA (mRNA), in adults with CF who are not eligible for CFTR modulator therapy or who are not able to take CFTR modulatory therapy.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40% or greater

  • Number of Visits:

    17

  • Length of Participation:

    7 months

• Restore CFTR ProteinEnrolling

  Phase 3 study of VX-121/tezacaftor/deutivacaftor in children 2 to 5 with cystic fibrosis , protocol number Vertex VX21-121-105 Cohort A2

  This study is taking place at multiple care centers across the U.S. It will look at safety and tolerability and how the body processes the drug VX-121/tezacaftor/deutivacaftor in participants with at least one triple-combination responsive CF mutation.

  • Age:

    2 Years to 5 Years

  • Mutation(s):

    Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    7

  • Length of Participation:

    7 weeks

• Anti-InfectiveEnrolling

  Study to evaluate inhaled RSP-1502 in adults with cystic fibrosis and Pseudomonas aeruginosa , protocol number Respirion RESPIR-102

  This study will look at the safety of inhaled RSP-1502, a drug intended to treat infections in the lung. RSP-1502, which includes the antibiotic tobramycin, will be compared to tobramycin alone. The study will measure the drug's safety, how well it works, and how the body processes it. Four doses of RSP-1502 will be tested to find the best dose. 

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40 to 90%

  • Number of Visits:

    4

  • Length of Participation:

    28 days

• ObservationalEnrolling

  REACH: An observational study for people with CF who do not take CFTR modulators , protocol number REACH-OB-23

  The REACH observational study will collect health information on people with CF 12 years and older who do not take CFTR modulators.

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    4

  • Length of Participation:

    12 months

• OtherEnrolling

  A study to evaluate the insulin-only Bionic Pancreas in people with cystic fibrosis 14 years of age or older who have cystic fibrosis-related diabetes (CFRD) , protocol number Bionic Pancreas CFRD IOBP V 1.0.

  This study will evaluate the effectiveness and safety of using the insulin-only Bionic Pancreas (BP) system compared to using one’s usual insulin delivery method.

  • Age:

    14 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    4

  • Length of Participation:

    7 months

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.